Manufacturer of Controlled Substances; Notice of Registration; Cedarburg Pharmaceuticals, Inc., 14297-14298 [2014-05496]
Download as PDF
<![CDATA[
14297
Federal Register / Vol. 79, No. 49 / Thursday, March 13, 2014 / Notices
Dated: February 19, 2014.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled
Substances; Notice of Registration;
Johnson Matthey, Inc.
[FR Doc. 2014–05488 Filed 3–12–14; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled
Substances; Notice of Application;
Cayman Chemical Company
Pursuant to 21 CFR 1301.33(a), this is
notice that on December 6, 2013,
Cayman Chemical Company, 1180 East
Ellsworth Road, Ann Arbor, Michigan
48108, made application by
correspondence to the Drug
Enforcement Administration (DEA) to
be registered as a bulk manufacturer of
the following basic classes of controlled
substances:
Drug
Schedule
2-(4-bromo-2,5-dimethoxyphenyl)N-(2-methoxybenzyl)
(25B–
NBOMe) (7536).
2-(4-chloro-2,5-dimethoxyphenyl)N-(2-methoxybenzyl)
(25C–
NBOMe) (7537).
2-(4-iodo-2,5-dimethoxyphenyl)-N(2-methoxybenzyl)
(25I–
NBOMe) (7538).
I
I
I
TKELLEY on DSK3SPTVN1PROD with NOTICES
The company plans to manufacture
the listed controlled substances, and
distribute those substances to its
research and forensics customers for
drug testing and analysis.
Any other such applicant, and any
person who is presently registered with
the DEA to manufacture such
substances, may file comments or
objections to the issuance of the
proposed registration pursuant to 21
CFR 1301.33(a).
Any such written comments or
objections should be addressed, in
quintuplicate, to the Drug Enforcement
Administration, Office of Diversion
Control, Federal Register Representative
(ODW), 8701 Morrissette Drive,
Springfield, Virginia 22152; and must be
filed no later than May 12, 2014.
Dated: Signed February 19, 2014.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. 2014–05493 Filed 3–12–14; 8:45 am]
BILLING CODE 4410–09–P
VerDate Mar<15>2010
17:33 Mar 12, 2014
Jkt 232001
By Notice dated November 5, 2013,
and published in the Federal Register
on November 18, 2013, 78 FR 69132,
Johnson Matthey, Inc., Custom
Pharmaceuticals Department, 2003
Nolte Drive, West Deptford, New Jersey
08066–1742, made application by
renewal to the Drug Enforcement
Administration (DEA) to be registered as
a bulk manufacturer of the following
basic classes of controlled substances:
company’s background and history.
Therefore, pursuant to 21 U.S.C. 823(a),
and in accordance with 21 CFR 1301.33,
the above named company is granted
registration as a bulk manufacturer of
the basic classes of controlled
substances listed.
Dated: February 19, 2014.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. 2014–05503 Filed 3–12–14; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Drug
Schedule
Gamma
Hydroxybutyric
Acid
(2010).
Tetrahydrocannabinols (7370) .....
Dihydromorphine (9145) ...............
Difenoxin (9168) ...........................
Propiram (9649) ...........................
Amphetamine (1100) ....................
Methamphetamine (1105) ............
Lisdexamfetamine (1205) .............
Methylphenidate (1724) ................
Nabilone (7379) ............................
Cocaine (9041) .............................
Codeine (9050) .............................
Dihydrocodeine (9120) .................
Oxycodone (9143) ........................
Hydromorphone (9150) ................
Diphenoxylate (9170) ...................
Ecgonine (9180) ...........................
Hydrocodone (9193) .....................
Meperidine (9230) ........................
Methadone (9250) ........................
Methadone intermediate (9254) ...
Morphine (9300) ...........................
Thebaine (9333) ...........................
Oxymorphone (9652) ...................
Noroxymorphone (9668) ..............
Alfentanil (9737) ...........................
Remifentanil (9739) ......................
Sufentanil (9740) ..........................
Tapentadol (9780) ........................
Fentanyl (9801) ............................
I
I
I
I
I
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
The company plans to manufacture
the listed controlled substances in bulk
for sale to its customers.
No comments or objections have been
received. The DEA has considered the
factors in 21 U.S.C. 823(a), and
determined that the registration of
Johnson Matthey, Inc., to manufacture
the listed basic classes of controlled
substances is consistent with the public
interest at this time. The DEA has
investigated, Johnson Matthey, Inc., to
ensure that the company’s registration is
consistent with the public interest. The
investigation has included inspection
and testing of the company’s physical
security systems, verification of the
company’s compliance with state and
local laws, and a review of the
PO 00000
Frm 00086
Fmt 4703
Sfmt 4703
Manufacturer of Controlled
Substances; Notice of Registration;
Cedarburg Pharmaceuticals, Inc.
By Notice dated October 16, 2013, and
published in the Federal Register on
October 25, 2013, 78 FR 64017,
Cedarburg Pharmaceuticals, Inc., 870
Badger Circle, Grafton, Wisconsin
53024, made application by renewal to
the Drug Enforcement Administration
(DEA) to be registered as a bulk
manufacturer of the following basic
classes of controlled substances:
Drug
4-Anilino-N-phenethyl-4-piperidine
(8333).
Remifentanil (9739) ......................
Fentanyl (9801) ............................
Schedule
II
II
II
The company plans to manufacture
the listed controlled substances in bulk
for distribution to its customers.
No comments or objections have been
received. The DEA has considered the
factors in 21 U.S.C. 823(a), and
determined that the registration of
Cedarburg Pharmaceuticals, Inc. to
manufacture the listed basic classes of
controlled substances is consistent with
the public interest at this time. The DEA
has investigated Cedarburg
Pharmaceuticals, Inc. to ensure that the
company’s registration is consistent
with the public interest. The
investigation has included inspection
and testing of the company’s physical
security systems, verification of the
company’s compliance with state and
local laws, and a review of the
company’s background and history.
Therefore, pursuant to 21 U.S.C. 823(a)
and in accordance with 21 CFR 1301.33,
the above named company is granted
registration as a bulk manufacturer of
the basic classes of controlled
substances listed.
E:\FR\FM\13MRN1.SGM
13MRN1
14298
Federal Register / Vol. 79, No. 49 / Thursday, March 13, 2014 / Notices
Dated: February 19, 2014.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled
Substances; Notice of Registration;
Stepan Company
[FR Doc. 2014–05496 Filed 3–12–14; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled
Substances; Notice of Registration;
Morton Grove Pharmaceuticals
TKELLEY on DSK3SPTVN1PROD with NOTICES
By Notice dated November 5, 2013,
and published in the Federal Register
on November 18, 2013, 78 FR 69133,
Morton Grove Pharmaceuticals, 6451
Main Street, Morton Grove, Illinois
60053–2633, made application by
renewal to the Drug Enforcement
Administration (DEA) to be registered as
a bulk manufacturer of Gamma
Hydroxybutyric Acid (2010), a basic
class of controlled substance listed in
schedule I.
The company plans to manufacture a
controlled substance for product
development.
No comments or objections have been
received. The DEA has considered the
factors in 21 U.S.C. 823(a), and
determined that the registration of
Morton Grove Pharmaceuticals to
manufacture the listed basic class of
controlled substance is consistent with
the public interest at this time. The DEA
has investigated Morton Grove
Pharmaceuticals to ensure that the
company’s registration is consistent
with the public interest. The
investigation has included inspection
and testing of the company’s physical
security systems, verification of the
company’s compliance with state and
local laws, and a review of the
company’s background and history.
Therefore, pursuant to 21 U.S.C. 823(a)
and in accordance with 21 CFR 1301.33,
the above named company is granted
registration as a bulk manufacturer of
the basic class of controlled substance
listed.
Dated: February 19, 2014.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. 2014–05505 Filed 3–12–14; 8:45 am]
17:33 Mar 12, 2014
Drug
Schedule
Cocaine (9041) .............................
Ecgonine (9180) ...........................
II
II
The company plans to manufacture
the listed controlled substances in bulk
for distribution to its customers.
No comments or objections have been
received. The DEA has considered the
factors in 21 U.S.C. 823(a) and
determined that the registration of
Stepan Company to manufacture the
listed basic classes of controlled
substances is consistent with the public
interest at this time. The DEA has
investigated Stepan Company to ensure
that the company’s registration is
consistent with the public interest. The
investigation has included inspection
and testing of the company’s physical
security systems, verification of the
company’s compliance with state and
local laws, and a review of the
company’s background and history.
Therefore, pursuant to 21 U.S.C. 823,
and in accordance with 21 CFR 1301.33,
the above named company is granted
registration as a bulk manufacturer of
the basic classes of controlled
substances listed.
Dated: February 19, 2014.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. 2014–05494 Filed 3–12–14; 8:45 am]
BILLING CODE 4410–09–P
Jkt 232001
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled
Substances; Notice of Registration;
Research Triangle Institute
PO 00000
Frm 00087
Fmt 4703
Sfmt 4703
Dated: February 19, 2014.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. 2014–05507 Filed 3–12–14; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled
Substances; Notice of Registration;
Nektar Therapeutics
By Notice dated October 10, 2013, and
published in the Federal Register on
October 25, 2013, 78 FR 64018,
BILLING CODE 4410–09–P
VerDate Mar<15>2010
By Notice dated October 9, 2013, and
published in the Federal Register on
October 25, 2013, 78 FR 64018, Stepan
Company, Natural Products Dept., 100
W. Hunter Avenue, Maywood, New
Jersey 07607, made application by
renewal to the Drug Enforcement
Administration (DEA) to be registered as
a bulk manufacturer of the following
basic classes of controlled substances:
Research Triangle Institute, Hermann
Building East Institute Drive, P.O. Box
12194, Research Triangle Park, North
Carolina 27709, made application by
letter to the Drug Enforcement
Administration (DEA) to be registered as
a bulk manufacturer of
Tetrahydrocannabinols (7370), a basic
class of controlled substance listed in
schedule I.
The company plans to provide small
quantities to commercial customers for
use in preparing test kits, reagents, and
reference standards.
The company plans to bulk
manufacture a synthetic
Tetrahydrocannabinol. No other activity
for this drug code is authorized for this
registration.
No comments or objections have been
received. The DEA has considered the
factors in 21 U.S.C. 823(a) and
determined that the registration of
Research Triangle Institute to
manufacture the listed basic class of
controlled substance is consistent with
the public interest at this time. The DEA
has investigated Research Triangle
Institute to ensure that the company’s
registration is consistent with the public
interest. The investigation has included
inspection and testing of the company’s
physical security systems, verification
of the company’s compliance with state
and local laws, and a review of the
company’s background and history.
Therefore, pursuant to 21 U.S.C. 823
and in accordance with 21 CFR 1301.33,
the above named company is granted
registration as a bulk manufacturer of
the basic class of controlled substance
listed.
By Notice dated September 27, 2013,
and published in the Federal Register
on October 25, 2013, 78 FR 64018,
Nektar Therapeutics, 1112 Church
Street, Huntsville, Alabama 35801,
made application by renewal to the
Drug Enforcement Administration
(DEA) to be registered as a bulk
manufacturer of Fentanyl (9801), a basic
E:\FR\FM\13MRN1.SGM
13MRN1
]]>Agencies
[Federal Register Volume 79, Number 49 (Thursday, March 13, 2014)]
[Notices]
[Pages 14297-14298]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2014-05496]
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled Substances; Notice of Registration;
Cedarburg Pharmaceuticals, Inc.
By Notice dated October 16, 2013, and published in the Federal
Register on October 25, 2013, 78 FR 64017, Cedarburg Pharmaceuticals,
Inc., 870 Badger Circle, Grafton, Wisconsin 53024, made application by
renewal to the Drug Enforcement Administration (DEA) to be registered
as a bulk manufacturer of the following basic classes of controlled
substances:
------------------------------------------------------------------------
Drug Schedule
------------------------------------------------------------------------
4-Anilino-N-phenethyl-4-piperidine (8333).. II
Remifentanil (9739)........................ II
Fentanyl (9801)............................ II
------------------------------------------------------------------------
The company plans to manufacture the listed controlled substances
in bulk for distribution to its customers.
No comments or objections have been received. The DEA has
considered the factors in 21 U.S.C. 823(a), and determined that the
registration of Cedarburg Pharmaceuticals, Inc. to manufacture the
listed basic classes of controlled substances is consistent with the
public interest at this time. The DEA has investigated Cedarburg
Pharmaceuticals, Inc. to ensure that the company's registration is
consistent with the public interest. The investigation has included
inspection and testing of the company's physical security systems,
verification of the company's compliance with state and local laws, and
a review of the company's background and history. Therefore, pursuant
to 21 U.S.C. 823(a) and in accordance with 21 CFR 1301.33, the above
named company is granted registration as a bulk manufacturer of the
basic classes of controlled substances listed.
[[Page 14298]]
Dated: February 19, 2014.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion Control, Drug
Enforcement Administration.
[FR Doc. 2014-05496 Filed 3-12-14; 8:45 am]
BILLING CODE 4410-09-P
